Brief: 3D Medicines Biotechnology Shanghai Says Phase II Study Protocol Of Envafolimab Allowed To Proceed By U.S. FDA
30/12/2022 13:49
Dec 30 (Reuters) - 3D Medicines Biotechnology Shanghai
Co Ltd 1244.HK :
* A PHASE II STUDY PROTOCOL OF ENVAFOLIMAB HAS BEEN ALLOWED
TO
PROCEED BY U.S. FOOD AND DRUG ADMINISTRATION
Further company coverage: 1244.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 3D Medicines
See all newsBrief: 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
Brief: 3D Medicines Inc Says Zhang Jing Resigns As CFO
Brief: 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
Brief: 3D Medicines Says Envafoimab Granted Orphan Drug Designation
Brief: 3D Medicines Inc Enters Strategic Agreement With Catug Biotechnology